glimepiride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1300 93479-97-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • glimepiride
  • diameprid
  • glimax
  • glimperide
  • glirid
  • Molecular weight: 490.62
  • Formula: C24H34N4O5S
  • CLOGP: 3.96
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 124.68
  • ALOGS: -4.11
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.19 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 30, 1995 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1677.85 10.78 846 38365 53503 46593348
Blood glucose increased 475.65 10.78 430 38781 71583 46575268
Lactic acidosis 326.54 10.78 252 38959 33657 46613194
Hypoglycaemic coma 293.40 10.78 102 39109 2472 46644379
Diabetes mellitus inadequate control 208.60 10.78 133 39078 13081 46633770
Blood glucose decreased 203.06 10.78 150 39061 18742 46628109
Glycosylated haemoglobin increased 193.20 10.78 118 39093 10758 46636093
Hypoglycaemic encephalopathy 145.24 10.78 36 39175 245 46646606
Myocardial infarction 136.82 10.78 272 38939 97256 46549595
Cardiac failure congestive 136.12 10.78 262 38949 91488 46555363
Acute kidney injury 136.00 10.78 471 38740 235384 46411467
Hyperglycaemia 117.33 10.78 146 39065 34925 46611926
Diabetes mellitus 96.04 10.78 160 39051 49905 46596946
Rheumatoid arthritis 89.55 10.78 45 39166 240170 46406681
Drug ineffective 86.76 10.78 287 38924 677551 45969300
Coronary artery disease 77.31 10.78 117 39094 33635 46613216
Diabetic metabolic decompensation 69.79 10.78 29 39182 1156 46645695
Diabetic ketoacidosis 67.71 10.78 80 39131 18130 46628721
Pancreatitis 67.61 10.78 127 39084 43500 46603351
Cerebral infarction 63.73 10.78 88 39123 23278 46623573
Hyperkalaemia 61.15 10.78 133 39078 50576 46596275
Maternal exposure during pregnancy 59.20 10.78 8 39203 102541 46544310
Blood glucose fluctuation 58.72 10.78 39 39172 4107 46642744
Exposure during pregnancy 56.74 10.78 11 39200 108201 46538650
Pancreatic carcinoma 50.90 10.78 43 39168 6514 46640337
Neuroglycopenia 49.86 10.78 11 39200 41 46646810
Decreased appetite 48.28 10.78 303 38908 193533 46453318
Pancreatitis acute 45.69 10.78 78 39133 24794 46622057
Drug intolerance 44.47 10.78 35 39176 147014 46499837
Altered state of consciousness 42.60 10.78 73 39138 23275 46623576
Joint swelling 42.57 10.78 46 39165 166027 46480824
Contraindicated product administered 42.17 10.78 8 39203 79939 46566912
Renal failure 42.11 10.78 198 39013 113396 46533455
MELAS syndrome 40.63 10.78 11 39200 110 46646741
Blood glucose abnormal 40.36 10.78 38 39173 6634 46640217
Off label use 39.21 10.78 175 39036 379666 46267185
Infusion related reaction 39.12 10.78 18 39193 101190 46545661
Sopor 38.84 10.78 64 39147 19764 46627087
Postprandial hypoglycaemia 37.42 10.78 9 39202 53 46646798
Synovitis 37.12 10.78 4 39207 61071 46585780
Systemic lupus erythematosus 35.51 10.78 6 39205 65174 46581677
Drug hypersensitivity 35.45 10.78 97 39114 243728 46403123
Metabolic acidosis 35.11 10.78 91 39120 38689 46608162
Bladder cancer 34.70 10.78 25 39186 3001 46643850
Euglycaemic diabetic ketoacidosis 33.57 10.78 21 39190 1995 46644856
Cold sweat 32.55 10.78 43 39168 10902 46635949
Renal impairment 32.35 10.78 136 39075 74236 46572615
Insulin C-peptide increased 31.48 10.78 8 39203 61 46646790
Ketoacidosis 30.83 10.78 26 39185 3929 46642922
Pain 29.78 10.78 257 38954 476691 46170160
Weight decreased 29.30 10.78 288 38923 210561 46436290
Ketosis 29.20 10.78 12 39199 465 46646386
Thrombotic cerebral infarction 27.64 10.78 8 39203 104 46646747
Blood creatinine increased 27.44 10.78 132 39079 76271 46570580
Shock hypoglycaemic 27.23 10.78 8 39203 110 46646741
Anuria 26.69 10.78 40 39171 11391 46635460
Pyelonephritis acute 25.88 10.78 24 39187 4110 46642741
Hypoparathyroidism 25.58 10.78 12 39199 641 46646210
Cerebrovascular accident 25.14 10.78 158 39053 100881 46545970
Hyperinsulinaemia 25.09 10.78 7 39204 79 46646772
Pemphigus 25.03 10.78 4 39207 45270 46601581
Hyperhidrosis 24.99 10.78 144 39067 89164 46557687
Dehydration 24.69 10.78 223 38988 159317 46487534
Blood urea increased 24.52 10.78 61 39150 25291 46621560
Diabetic retinopathy 24.10 10.78 18 39193 2284 46644567
Hypoglycaemic unconsciousness 24.06 10.78 12 39199 734 46646117
Cardiac failure 23.75 10.78 131 39080 79817 46567034
Cholelithiasis 23.71 10.78 79 39132 38602 46608249
Musculoskeletal stiffness 23.09 10.78 29 39182 97964 46548887
Drug level increased 22.94 10.78 49 39162 18392 46628459
Diarrhoea 22.59 10.78 622 38589 558980 46087871
Biopsy skin abnormal 21.97 10.78 7 39204 128 46646723
Injection site nodule 21.94 10.78 20 39191 3351 46643500
Diabetic neuropathy 21.81 10.78 21 39190 3768 46643083
Hepatic function abnormal 21.73 10.78 71 39140 34350 46612501
Abortion spontaneous 21.71 10.78 5 39206 43641 46603210
Medication error 21.56 10.78 66 39145 30845 46616006
Fatigue 21.54 10.78 371 38840 608326 46038525
Loss of consciousness 20.86 10.78 159 39052 108079 46538772
Fall 20.84 10.78 390 38821 328707 46318144
Depressed level of consciousness 20.69 10.78 87 39124 47482 46599369
Urogenital haemorrhage 20.68 10.78 7 39204 156 46646695
Muscle discomfort 20.59 10.78 6 39205 80 46646771
Completed suicide 20.48 10.78 59 39152 145861 46500990
Nasopharyngitis 20.37 10.78 64 39147 153934 46492917
Glossodynia 20.32 10.78 6 39205 44367 46602484
Hypersensitivity 20.21 10.78 62 39149 150259 46496592
Therapeutic product effect decreased 19.93 10.78 24 39187 82577 46564274
Hypothermia 19.53 10.78 36 39175 12147 46634704
Drug interaction 19.43 10.78 258 38953 202836 46444015
Headache 19.43 10.78 284 38927 478068 46168783
Differential white blood cell count abnormal 19.41 10.78 10 39201 655 46646196
Neutropenia 19.30 10.78 59 39152 143145 46503706
Drug abuse 19.27 10.78 15 39196 63393 46583458
Blood insulin increased 18.82 10.78 6 39205 110 46646741
Urine ketone body present 18.61 10.78 15 39196 2127 46644724
Sinusitis 18.55 10.78 52 39159 129716 46517135
Treatment failure 18.53 10.78 31 39180 93056 46553795
Diabetic complication 18.37 10.78 11 39200 966 46645885
Product use in unapproved indication 18.03 10.78 30 39181 90243 46556608
Anti-insulin antibody increased 17.88 10.78 5 39206 57 46646794
Anaemia vitamin B12 deficiency 17.85 10.78 8 39203 384 46646467
Dermatitis exfoliative 17.84 10.78 23 39188 5693 46641158
Bradypnoea 17.79 10.78 17 39194 3022 46643829
Rhabdomyolysis 17.72 10.78 76 39135 41833 46605018
Acute myocardial infarction 17.65 10.78 63 39148 31861 46614990
Hyporesponsive to stimuli 16.96 10.78 10 39201 854 46645997
Alopecia 16.60 10.78 75 39136 162339 46484512
Glycosylated haemoglobin abnormal 16.56 10.78 5 39206 76 46646775
Foetal exposure during pregnancy 16.37 10.78 3 39208 30744 46616107
Heart injury 15.98 10.78 11 39200 1228 46645623
Arthralgia 15.65 10.78 214 38997 364389 46282462
Oliguria 15.47 10.78 27 39184 8732 46638119
Oedema peripheral 15.31 10.78 203 39008 159503 46487348
Migraine 15.20 10.78 22 39189 70004 46576847
Pancreatic carcinoma metastatic 15.11 10.78 14 39197 2394 46644457
Hypomagnesaemia 15.10 10.78 47 39164 22163 46624688
Pemphigoid 14.87 10.78 21 39190 5670 46641181
Restlessness 14.65 10.78 51 39160 25473 46621378
Hepatic steatosis 14.64 10.78 49 39162 23993 46622858
Transient ischaemic attack 14.53 10.78 63 39148 34840 46612011
Musculoskeletal pain 14.29 10.78 23 39188 70105 46576746
Retinal haemorrhage 14.23 10.78 19 39192 4864 46641987
Product use issue 14.22 10.78 37 39174 94607 46552244
Mixed anxiety and depressive disorder 14.08 10.78 5 39206 129 46646722
Myocardial ischaemia 13.75 10.78 32 39179 12717 46634134
Pregnancy 13.71 10.78 3 39208 27134 46619717
Blood potassium increased 13.53 10.78 38 39173 16929 46629922
Febrile neutropenia 13.46 10.78 38 39173 94589 46552262
Arteriosclerosis 13.44 10.78 27 39184 9706 46637145
Asthenia 13.41 10.78 349 38862 310726 46336125
Carotid arteriosclerosis 13.35 10.78 9 39202 971 46645880
Hyperthyroidism 13.30 10.78 30 39181 11681 46635170
Liver disorder 13.11 10.78 64 39147 37182 46609669
Blood creatine phosphokinase increased 13.07 10.78 52 39159 27672 46619179
Azotaemia 12.79 10.78 17 39194 4334 46642517
Gastroenteritis 12.71 10.78 47 39164 24172 46622679
Phobia 12.51 10.78 6 39205 337 46646514
Pylorus dilatation 12.43 10.78 3 39208 18 46646833
Dry eye 12.33 10.78 5 39206 30317 46616534
Anaphylactic reaction 12.21 10.78 16 39195 53096 46593755
Hyperventilation 12.11 10.78 19 39192 5628 46641223
Macular oedema 12.02 10.78 16 39195 4085 46642766
Capillary leak syndrome 11.85 10.78 11 39200 1886 46644965
Infection 11.75 10.78 65 39146 133527 46513324
Compartment syndrome 11.36 10.78 11 39200 1988 46644863
Pulse abnormal 11.18 10.78 10 39201 1634 46645217
Cholecystitis 11.14 10.78 32 39179 14434 46632417
Blood triglycerides increased 11.02 10.78 28 39183 11755 46635096
Renal disorder 10.98 10.78 48 39163 26638 46620213
Angina pectoris 10.89 10.78 48 39163 26727 46620124
Lipase increased 10.86 10.78 23 39188 8580 46638271
Type 2 diabetes mellitus 10.79 10.78 39 39172 19836 46627015

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1400.06 10.85 879 41426 50102 29860071
Blood glucose increased 329.91 10.85 420 41885 61110 29849063
Hypoglycaemic coma 307.78 10.85 118 42187 2213 29907960
Lactic acidosis 246.02 10.85 260 42045 30953 29879220
Diabetes mellitus inadequate control 223.07 10.85 167 42138 12595 29897578
Glycosylated haemoglobin increased 202.04 10.85 140 42165 9351 29900822
Myocardial infarction 179.23 10.85 483 41822 125142 29785031
Coronary artery disease 158.97 10.85 266 42039 49446 29860727
Cardiac failure congestive 143.56 10.85 347 41958 84060 29826113
Cerebral infarction 139.47 10.85 179 42126 26194 29883979
Bladder cancer 118.08 10.85 100 42205 9002 29901171
Pancreatitis 104.47 10.85 186 42119 36304 29873869
Blood glucose decreased 99.69 10.85 107 42198 12946 29897227
Hyperglycaemia 88.90 10.85 170 42135 35030 29875143
Diabetes mellitus 83.06 10.85 183 42122 41682 29868491
Pancreatic carcinoma 79.62 10.85 75 42230 7762 29902411
Drug abuse 74.60 10.85 13 42292 82059 29828114
Pancreatitis acute 73.55 10.85 131 42174 25564 29884609
Off label use 67.14 10.85 159 42146 249131 29661042
Hyperkalaemia 60.59 10.85 218 42087 65792 29844381
Hypoglycaemic encephalopathy 58.24 10.85 19 42286 216 29909957
Diabetic ketoacidosis 57.09 10.85 90 42215 15896 29894277
Interstitial lung disease 56.26 10.85 200 42105 59997 29850176
Cerebrovascular accident 56.01 10.85 250 42055 83227 29826946
Toxicity to various agents 53.44 10.85 106 42199 177077 29733096
Hepatic function abnormal 51.51 10.85 153 42152 41792 29868381
Product use in unapproved indication 51.18 10.85 20 42285 73673 29836500
Acute kidney injury 50.33 10.85 599 41706 273243 29636930
Altered state of consciousness 46.38 10.85 93 42212 19826 29890347
Neutropenia 45.95 10.85 69 42236 128471 29781702
Acute myocardial infarction 42.88 10.85 168 42137 52771 29857402
Blood lactic acid 42.28 10.85 17 42288 363 29909810
Heart injury 36.88 10.85 24 42281 1442 29908731
Pemphigoid 36.52 10.85 49 42256 7479 29902694
Drug ineffective 35.08 10.85 310 41995 340077 29570096
Gastric cancer 33.33 10.85 38 42267 4912 29905261
Diabetic nephropathy 31.62 10.85 24 42281 1845 29908328
Death 31.09 10.85 339 41966 356944 29553229
Treatment failure 30.41 10.85 6 42299 34673 29875500
Decreased appetite 30.15 10.85 334 41971 149576 29760597
Bladder transitional cell carcinoma 29.87 10.85 26 42279 2427 29907746
Urine ketone body present 29.58 10.85 18 42287 961 29909212
Myocardial ischaemia 29.15 10.85 71 42234 17246 29892927
Renal impairment 29.02 10.85 211 42094 83973 29826200
Diabetic metabolic decompensation 28.97 10.85 20 42285 1326 29908847
Dyslalia 28.31 10.85 14 42291 494 29909679
Febrile neutropenia 27.87 10.85 69 42236 106624 29803549
Completed suicide 27.87 10.85 62 42243 99430 29810743
Blood glucose abnormal 25.15 10.85 34 42271 5225 29904948
Hypoglycaemic unconsciousness 24.65 10.85 15 42290 801 29909372
Liver disorder 24.60 10.85 95 42210 29627 29880546
Blindness transient 24.33 10.85 21 42284 1938 29908235
Diabetic retinopathy 24.29 10.85 20 42285 1730 29908443
Pancreatic carcinoma metastatic 23.70 10.85 26 42279 3221 29906952
Lipase increased 23.25 10.85 43 42262 8633 29901540
Shock 22.24 10.85 77 42228 22782 29887391
Ischaemic cardiomyopathy 21.85 10.85 35 42270 6262 29903911
Cardiac failure 21.65 10.85 196 42109 83222 29826951
Latent autoimmune diabetes in adults 21.09 10.85 6 42299 41 29910132
Coronary artery stenosis 20.69 10.85 42 42263 9028 29901145
Glycosylated haemoglobin decreased 20.25 10.85 10 42295 352 29909821
Amylase increased 19.63 10.85 32 42273 5809 29904364
Blood glucose fluctuation 19.57 10.85 25 42280 3636 29906537
Lacunar infarction 19.21 10.85 23 42282 3132 29907041
Joint swelling 18.98 10.85 23 42282 46923 29863250
Angina pectoris 18.71 10.85 87 42218 29431 29880742
Drug resistance 18.70 10.85 3 42302 20130 29890043
Product commingling 18.42 10.85 5 42300 28 29910145
Brain stem infarction 18.28 10.85 15 42290 1291 29908882
Rheumatoid arthritis 17.94 10.85 19 42286 41178 29868995
Haemorrhagic cerebral infarction 17.68 10.85 12 42293 774 29909399
Pyrexia 17.42 10.85 302 42003 294187 29615986
Lower respiratory tract infection 17.33 10.85 8 42297 26706 29883467
Cytomegalovirus infection 17.14 10.85 6 42299 23668 29886505
Mucosal inflammation 17.07 10.85 11 42294 30483 29879690
Hypothermia 16.93 10.85 40 42265 9527 29900646
Arteriosclerosis 16.74 10.85 43 42262 10790 29899383
Albumin urine present 16.69 10.85 9 42296 381 29909792
Blood lactate dehydrogenase increased 16.36 10.85 65 42240 20536 29889637
Aggression 16.09 10.85 17 42288 36890 29873283
Thrombotic cerebral infarction 15.80 10.85 8 42297 297 29909876
Coronary artery bypass 15.64 10.85 27 42278 5135 29905038
Coronary arterial stent insertion 15.51 10.85 24 42281 4170 29906003
Nephrogenic anaemia 15.39 10.85 17 42288 2122 29908051
Headache 15.38 10.85 174 42131 182132 29728041
Infusion related reaction 15.23 10.85 21 42284 40543 29869630
Carotid artery stenosis 14.97 10.85 25 42280 4629 29905544
Cardiac disorder 14.91 10.85 102 42203 39791 29870382
Diabetic gangrene 14.79 10.85 7 42298 224 29909949
Hepatocellular carcinoma 14.70 10.85 38 42267 9572 29900601
Blood urea increased 14.69 10.85 85 42220 31296 29878877
Leukopenia 14.13 10.85 37 42268 56122 29854051
Weight decreased 14.09 10.85 295 42010 150626 29759547
Blood creatinine increased 13.78 10.85 193 42112 91182 29818991
Diabetic neuropathy 13.73 10.85 22 42283 3937 29906236
Renal failure 13.69 10.85 257 42048 128709 29781464
Insulin resistance 13.65 10.85 9 42296 553 29909620
Transient ischaemic attack 13.64 10.85 71 42234 25129 29885044
Anxiety 13.58 10.85 73 42232 89798 29820375
Metabolic acidosis 13.53 10.85 95 42210 37366 29872807
Acute coronary syndrome 13.44 10.85 46 42259 13527 29896646
Gastric adenoma 13.40 10.85 3 42302 6 29910167
Anti-insulin antibody increased 13.28 10.85 5 42300 89 29910084
Hyperglycaemic hyperosmolar nonketotic syndrome 13.25 10.85 11 42294 963 29909210
Symmetrical drug-related intertriginous and flexural exanthema 13.22 10.85 6 42299 174 29909999
Ketonuria 13.06 10.85 9 42296 595 29909578
Colon cancer 12.70 10.85 33 42272 8339 29901834
Blood triglycerides increased 12.59 10.85 46 42259 13971 29896202
Pancreatitis chronic 12.53 10.85 14 42291 1770 29908403
Respiratory tract haemorrhage 12.43 10.85 10 42295 837 29909336
Thrombocytopenia 12.27 10.85 129 42176 136915 29773258
Bile duct cancer 12.21 10.85 9 42296 662 29909511
Blood lactic acid increased 12.13 10.85 26 42279 5804 29904369
Hyperuricaemia 12.11 10.85 30 42275 7364 29902809
Hospitalisation 12.08 10.85 28 42277 44291 29865882
Arthralgia 12.08 10.85 128 42177 135663 29774510
Adenocarcinoma pancreas 11.78 10.85 12 42293 1366 29908807
Bladder neoplasm 11.74 10.85 11 42294 1130 29909043
Respiratory alkalosis 11.66 10.85 12 42293 1382 29908791
Cardiovascular disorder 11.63 10.85 38 42267 10914 29899259
Peritonitis 11.57 10.85 8 42297 21367 29888806
Angina unstable 11.57 10.85 41 42264 12269 29897904
Pain 11.52 10.85 173 42132 172468 29737705
Fasting 11.51 10.85 3 42302 14 29910159
Pancreatic neuroendocrine tumour 11.46 10.85 6 42299 239 29909934
Suicidal ideation 11.38 10.85 21 42284 36093 29874080
Retinal aneurysm 11.32 10.85 5 42300 136 29910037
Hepatic cancer 11.18 10.85 27 42278 6521 29903652
Hypersensitivity 11.15 10.85 39 42266 53989 29856184
Product use issue 11.06 10.85 31 42274 45985 29864188
Oedema peripheral 10.91 10.85 210 42095 105622 29804551
Hemiplegia 10.88 10.85 27 42278 6634 29903539

Pharmacologic Action:

SourceCodeDescription
ATC A10BB12 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sulfonylureas
ATC A10BD04 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
FDA CS M0020795 Sulfonylurea Compounds
FDA EPC N0000175608 Sulfonylurea
CHEBI has role CHEBI:35526 hypoglycemic drug
CHEBI has role CHEBI:90415 insulin secretagogues
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Treatment Refractory Type 2 Diabetes Mellitus indication
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Hepatic porphyria contraindication 55056006 DOID:3133
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Kidney disease contraindication 90708001 DOID:557
Fracture of bone contraindication 125605004
Autonomic dysreflexia contraindication 129618003
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.31 acidic
pKa2 13.98 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Ki 9.24 WOMBAT-PK CHEMBL
Sulfonylurea receptor 2, Kir6.2 Ion channel BLOCKER Ki 7.98 WOMBAT-PK

External reference:

IDSource
4020945 VUID
N0000148425 NUI
D00593 KEGG_DRUG
4020945 VANDF
C0061323 UMLSCUI
CHEBI:5383 CHEBI
GMR PDB_CHEM_ID
CHEMBL1481 ChEMBL_ID
DB00222 DRUGBANK_ID
C057619 MESH_SUPPLEMENTAL_RECORD_UI
6820 IUPHAR_LIGAND_ID
5718 INN_ID
6KY687524K UNII
3476 PUBCHEM_CID
25789 RXNORM
4782 MMSL
72042 MMSL
d03864 MMSL
005624 NDDF
109079009 SNOMEDCT_US
386966003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AMARYL HUMAN PRESCRIPTION DRUG LABEL 1 0039-0221 TABLET 1 mg ORAL NDA 26 sections
AMARYL HUMAN PRESCRIPTION DRUG LABEL 1 0039-0222 TABLET 2 mg ORAL NDA 26 sections
AMARYL HUMAN PRESCRIPTION DRUG LABEL 1 0039-0223 TABLET 4 mg ORAL NDA 26 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 0440-6564 TABLET 1 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 0440-6565 TABLET 2 mg ORAL ANDA 26 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 0440-6566 TABLET 4 mg ORAL ANDA 26 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8332 TABLET 1 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8333 TABLET 2 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8334 TABLET 4 mg ORAL ANDA 25 sections
Pioglitazone hydrochloride and glimepiride HUMAN PRESCRIPTION DRUG LABEL 2 0781-5634 TABLET 2 mg ORAL ANDA 28 sections
Pioglitazone hydrochloride and glimepiride HUMAN PRESCRIPTION DRUG LABEL 2 0781-5635 TABLET 4 mg ORAL ANDA 28 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 10544-217 TABLET 2 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 10544-219 TABLET 4 mg ORAL ANDA 25 sections
Glimepiride Human Prescription Drug Label 1 16571-773 TABLET 1 mg ORAL ANDA 25 sections
Glimepiride Human Prescription Drug Label 1 16571-774 TABLET 2 mg ORAL ANDA 25 sections
Glimepiride Human Prescription Drug Label 1 16571-775 TABLET 4 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 16729-001 TABLET 1 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 16729-002 TABLET 2 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 16729-003 TABLET 4 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 21695-746 TABLET 2 mg ORAL ANDA 20 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 21695-747 TABLET 4 mg ORAL ANDA 20 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 21695-993 TABLET 1 mg ORAL ANDA 20 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 33261-831 TABLET 2 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 33261-892 TABLET 4 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 33261-961 TABLET 1 mg ORAL ANDA 26 sections
GLIMEPIRIDE HUMAN PRESCRIPTION DRUG LABEL 1 42549-498 TABLET 4 mg ORAL ANDA 28 sections
GLIMEPIRIDE HUMAN PRESCRIPTION DRUG LABEL 1 42549-499 TABLET 2 mg ORAL ANDA 24 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 42571-100 TABLET 1 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 42571-101 TABLET 2 mg ORAL ANDA 25 sections
Glimepiride HUMAN PRESCRIPTION DRUG LABEL 1 42571-102 TABLET 3 mg ORAL ANDA 25 sections